BioSpace News Archive

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Kuros Biosciences, a leader in next-generation bone graft technologies, announced that it will report its full-year financial results and provide a corporate update on its business on March 13, 2024.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, presented positive results from its first randomized controlled trial showing improved glycemic and patient-reported outcomes in type 1 diabetes with the Omnipod 5 Automated Insulin Delivery System.

International medical imaging IT and cybersecurity company Sectra’s enterprise imaging module for radiology once again received a top ranking in customer satisfaction surveys in the US, Canada and Europe.

KalVista Pharmaceuticals, Inc. today announced the acceptance of multiple abstracts at the 2024 HAEi Regional Conference meeting taking place in Panama City, Panama from March 15-17.

InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”) announced today it will issue preliminary fourth quarter and full year 2023 financial results on Thursday, March 14, 2024, before the market opens.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced The Lancet published one-year results from the pivotal PULSAR and PHOTON trials for EYLEA® HD (aflibercept) Injection 8 mg.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11, 2024 at 10:00 a.m. ET.

Augmedix announced today it will release fourth quarter and full year 2023 results after the market closes on Monday, March 18, 2024.

Arbutus Biopharma Corporation today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in Miami, FL.